Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., June 12, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 24, 2023 (the “Circular”) for the Annual General Me...
RESEARCH TRIANGLE PARK, N.C., June 06, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced Pedmarqsi™– known as PEDMARK ® in the U.S. – was granted marketing authorization...
~ Strong PEDMARK ® Commercial Momentum Building in 2023 with Broad Payor and Medicaid Coverage ~ ~ PEDMARK ® Permanent J-Code Effective April 1, 2023 ~ ~ Recent Positive CHMP Opinion in EU Recommending Approval of PEDMARQSI™ ~ ~ Compa...
RESEARCH TRIANGLE PARK, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2023 financial results before the opening of the U.S. financial...
~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~ ~ Positive CHMP Opinion Based on Clinical Results Demonstrating Prevention of Ototoxici...
~ U.S. Commercial Team in Place with PEDMARK ® Launch Off to Solid Start Following FDA Approval of PEDMARK ® in September 2022 ~ ~ Company Has Approximately $23.8 Million in Cash ~ RESEARCH TRIANGLE PARK, N.C., March 30, 2023 (GLOBE NEWSWIRE) -- Fen...
~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ Orphan Drug Exclusivity Provides Seven Years of Market Exclusivity for PEDMARK®...
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~ ~ The 5-year Survival Rate for Childhood Cancers Due to Major Treatment Advances is Now 85 Per...
The Beachbody Company Group, LLC (“Beachbody”) today announced the three-way business combination with Myx Fitness Holdings, LLC (“Myx”) and Forest Road Acquisition Corp. (NYSE:FRX) (“Forest Road”) was completed on June 25, 2021, creating t...
Forest Road Acquisition Corp. (NYSE:FRX) (“Forest Road”) today announced that its stockholders have voted to approve the proposed three-way business combination (the “Business Combination”) with The Beachbody Company Group, LLC (“Beachbody”) and...
News, Short Squeeze, Breakout and More Instantly...
Forest Road Acquisition Corp. Class A Company Name:
FRX Stock Symbol:
NYSE Market:
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of t...
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI ® , the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic soli...
~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NA...